使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, and welcome to the Amneal Pharmaceuticals second-quarter 2025 earnings call.
早安,歡迎參加 Amneal Pharmaceuticals 2025 年第二季財報電話會議。
I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
現在我將把電話會議交給 Amneal 投資人關係主管 Tony DiMeo。
Anthony Dimeo - Head of Investor Relations
Anthony Dimeo - Head of Investor Relations
Good morning, and thank you for joining Amneal Pharmaceuticals second-quarter 2025 earnings call. Today, we issued a press release supporting Q2 results. The earnings press release and presentation are available at amneal.com.
早安,感謝各位參加 Amneal Pharmaceuticals 2025 年第二季財報電話會議。今天我們發布新聞稿,說明第二季業績表現。財報新聞稿與簡報可於 amneal.com 取得。
Certain statements made on this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled cautionary statements on forward-looking statements for factors that may impact future performance.
本次電話會議中,針對非歷史事實之事項所作的某些陳述(包括但不限於管理層的展望或預測)屬於前瞻性陳述,且僅基於目前我們可取得的資訊。請參閱「前瞻性陳述之警示聲明」章節,了解可能影響未來表現的因素。
We also discussed non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation.
我們也將討論非 GAAP 衡量指標。關於這些指標的使用資訊以及與 GAAP 的調節,均載於財報新聞稿與簡報中。
On the call today are Chirag and Chintu Patel, Co-Founders and Co-CEOs; Tasos Konidaris, CFO; our commercial leaders, Andy Boyer for Affordable Medicines, Joe Renda for Specialty; and Jason Daly, Chief Legal Officer.
今天與會者包括共同創辦人暨共同執行長 Chirag 與 Chintu Patel;財務長 Tasos Konidaris;我們的商業團隊主管:Affordable Medicines 事業的 Andy Boyer、Specialty 事業的 Joe Renda;以及法務長 Jason Daly。
I will now hand the call over to Chirag.
現在我將把電話會議交給 Chirag。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Tony. Good morning, everyone.
謝謝你,Tony。各位早安。
The second quarter was another consecutive quarter of strong performance and growth with revenues of $720 million and adjusted EBITDA of $184 million. At the halfway point of the year and with confidence in our outlook, we're pleased to raise today's 2025 guidance. I'm so excited to walk you through the multiple growth drivers that are shaping the future of Amneal.
第二季再度連續一季展現強勁表現與成長,營收達 7.20 億美元,調整後 EBITDA 為 1.84 億美元。在年度過半之際,基於我們對展望的信心,我們很高興在今天上調 2025 年財測指引。我非常期待帶各位了解多項正在塑造 Amneal 未來的成長動能。
At Amneal, we focus each day on delivering innovative and affordable medicines that are essential for patients. Since our founding in 2002, we have methodically diversified beyond generics to build a broad and differentiated portfolio of branded and complex products. Amneal has stood out from the pack by generating consistent growth in each of the last six years. And we expect growth will continue in the years ahead.
在 Amneal,我們每天專注於提供對病患至關重要、兼具創新與可負擔性的藥品。自 2002 年成立以來,我們有系統地從學名藥擴展,打造廣泛且具差異化的品牌藥與複雜產品組合。Amneal 在過去六年每一年都實現穩健成長,因而在同業中脫穎而出。我們預期未來幾年仍將持續成長。
In the process, we have transformed Amneal and have entered the most exciting chapter yet. In this new chapter, there are a number of new growth drivers, including CREXONT for Parkinson's disease; Breykia autoinjector for severe migraine; new biosimilars such as biosimilar of XOLAIR; our continued cadence of 2030 new generics launches each year, particularly complex products including unique 505(b)(2) injectables for hospitals; and our GLP1 opportunity with Metsera.
在此過程中,我們已完成對 Amneal 的轉型,並進入迄今最令人振奮的新篇章。在這個新篇章中,有多項新的成長驅動因素,包括:用於帕金森氏症的 CREXONT;用於重度偏頭痛的 Breykia 自動注射器;新的生物相似藥(例如 XOLAIR 的生物相似藥);我們每年持續推出 20 至 30 項新的學名藥,尤其是複雜產品,包括供醫院使用、獨特的 505(b)(2) 注射劑;以及我們與 Metsera 合作的 GLP-1 機會。
These new medicines and new opportunities are designed to create substantial value by, one, advancing the standard of care and increasing access to medicines for patients; two, further expanding and differentiating our portfolio for providers; and three, adding to our growth story for investors.
這些新藥與新機會旨在透過以下方式創造可觀價值:第一,提升照護標準並增加病患取得藥品的可近性;第二,進一步擴大並差異化我們面向醫療提供者的產品組合;第三,為投資人增添我們的成長故事。
Over time, Amneal has strategically evolved from generics to innovative and complex medicines. And we are entering our new next phase of growth with strong momentum and clear confidence in growth ahead.
長期以來,Amneal 已策略性地從學名藥轉型至創新與複雜藥品。我們正以強勁動能進入下一個成長階段,並對未來成長抱持明確信心。
First, in our Specialty segment, the launch of CREXONT for Parkinson's disease continues to exceed our expectations in the first year of the launch. Uptake has been very strong, with US market share about at 2% and on track for over 3% by the end of the year.
首先,在我們的 Specialty 事業中,用於帕金森氏症的 CREXONT 上市後第一年持續超出我們的預期。市場採用速度非常強勁,美國市占率約為 2%,並有望在年底前超過 3%。
Notably, about 80% of CREXONT scripts are coming from IR patients, which is a strong indicator of our successful strategy to pursue the broader Parkinson's market. The patient testimonials have been inspiring, and we have highlighted a few in our earnings presentations. We are highly confident that CREXONT will achieve US peak sales of $300 million to $500 million.
值得注意的是,約 80% 的 CREXONT 處方來自 IR 病患,這強烈顯示我們切入更廣泛帕金森氏症市場的策略相當成功。病患的見證令人振奮,我們也在財報簡報中分享了其中幾則。我們高度有信心,CREXONT 在美國的峰值銷售額可達 3 億至 5 億美元。
Let me now turn to our newest specialty branded product, Breykia autoinjector, which received US FDA approval in May. Breykia is the first and only autoinjector form of DHE, a therapy that has been trusted for over 70 years for the acute treatment of migraine and cluster headaches in adults.
接著談我們最新的 Specialty 品牌產品 Breykia 自動注射器,該產品已於 5 月獲得美國 FDA 核准。Breykia 是首款且目前唯一的 DHE 自動注射器劑型;DHE 作為成人偏頭痛與叢集性頭痛急性治療用藥,已被信賴使用逾 70 年。
In the migraine treatment landscape, there is significant unmet need for patients who do not respond to existing therapies. This new product gives patients sustained headache relief when they need it the most and eliminates the need for time-consuming hospital visits.
在偏頭痛治療領域,對於對既有療法無反應的病患,仍存在顯著未被滿足的需求。這項新產品能在病患最需要時提供持續的頭痛緩解,並免除耗時的就醫住院就診需求。
We're excited to launch Breykia with a commercial rollout in October. We continue to see this as a $50 million to $100 million peak sales opportunity.
我們很期待於 10 月以商業化方式正式推出 Breykia。我們仍認為這是一個峰值銷售額 5,000 萬至 1 億美元的機會。
Second, in GLP-1s, we are advancing our partnership with Metsera to help deliver innovative therapies at scale. Amlean is Metsera's preferred global supplier for developed markets, including the US and Europe. We will also commercialize their products in 20 emerging markets, including India.
第二,在 GLP-1 領域,我們正推進與 Metsera 的合作夥伴關係,以協助大規模提供創新療法。Amneal 是 Metsera 在已開發市場(包括美國與歐洲)的首選全球供應商。我們也將在包含印度在內的 20 個新興市場商業化其產品。
We see GLP-1s as a long term opportunity, and we look forward to sharing more on this key catalyst over time.
我們將 GLP-1 視為長期機會,並期待隨時間推進,針對這項關鍵催化劑分享更多資訊。
Third, in our Affordable Medicine segment, growth continues to be fueled by our diversified portfolio of complex products and addition of new differentiated offerings. Broadly, we continue to see favorable macro trends across all three pillars, retail genetics, injectables, and biosimilars; and remain confident in our ability to execute, advance new innovations, and drive sustain sustainable growth long term.
第三,在我們的 Affordable Medicine 事業中,成長持續受惠於多元化的複雜產品組合,以及新增具差異化的新產品。整體而言,我們持續看到三大支柱——零售學名藥、注射劑與生物相似藥——皆有利的總體趨勢;並對我們的執行能力、推進新創新以及長期驅動可持續成長保持信心。
Within biosimilars specifically, we see a favorable long-term outlook for the US market. Over the next decade, the number of biologic patent expirations is expected to double compared to the past 10 years, creating significant opportunity, as approximately 90% of these products do not have biosimilars in development.
就生物相似藥而言,我們看好美國市場的長期前景。未來十年,生物製劑專利到期的數量預期將較過去十年倍增,帶來顯著機會;約有 90% 的這些產品目前尚未有生物相似藥在開發中。
At the same time, development timelines and costs are trending lower with fewer Phase 3 study requirements and generally less competition per molecule, excluding some of the largest biologics such as HUMIRA and STELARA.
同時,隨著第三期臨床試驗需求減少,且通常每個分子所面臨的競爭者較少(不含 HUMIRA 與 STELARA 等最大型生物製劑),開發時程與成本呈下降趨勢。
Against this backdrop, our biosimilars in-licensing strategy has enabled us to build an initial portfolio. With three biosimilars already commercialized and five more in development, we anticipate having six marketed biosimilars across eight presentations by 2027.
在此背景下,我們的生物相似藥引進授權(in-licensing)策略使我們得以建立初始產品組合。目前已有 3 款生物相似藥完成商業化,另有 5 款在開發中;我們預期至 2027 年將擁有 6 款已上市的生物相似藥,涵蓋 8 種劑型/規格呈現。
Specifically, biosimilar XOLAIR represents our largest biosimilar opportunity to date. As we have said in the past, our strategic intention is to be vertically integrated in biosimilars over time.
具體而言,XOLAIR 生物相似藥是我們迄今最大的生物相似藥機會。如同我們過去所述,我們的策略意圖是隨時間推進,在生物相似藥領域實現垂直整合。
Finally, performance in the AvKARE segment continues to be driven by a broad portfolio of products and new launches delivered across three distinct channels, government, distribution, and unit dose. This business, which adds stability and diversification to Amneal's portfolio, is expected to drive revenue of over $900 million by 2027.
最後,AvKARE 事業的表現持續由廣泛的產品組合與新產品上市所帶動,並透過三個不同通路交付:政府、經銷/配送,以及單位劑量(unit dose)。此一業務為 Amneal 的產品組合增添穩定性與多元化,預期至 2027 年將帶動營收超過 9 億美元。
In summary, Amneal has a diverse array of growth drivers that build upon our distinct market position, drive sustainable value creation, and improve access and care for patients. Our strategic goal is to be America's number one affordable medicines company, and we are well on our way.
總而言之,Amneal 擁有多元的成長動能,建立在我們獨特的市場定位之上,推動可持續的價值創造,並改善病患的可近性與照護。我們的策略目標是成為美國第一的平價藥品公司,而我們正穩步朝此目標邁進。
I'll now turn it over to Chintu.
接下來我把時間交給 Chintu。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Thank you, Chirag, and good morning, everyone. Let me begin by expressing my deep appreciation to our Amneal team. Your passion, resiliency and unwavering commitment continues to drive Amneal forward as a deeply purpose-driven company.
謝謝你,Chirag,各位早安。首先,讓我向 Amneal 團隊表達由衷的感謝。你們的熱情、韌性與堅定不移的承諾,持續推動 Amneal 作為一家以使命為導向的公司不斷向前。
This morning, I will provide an update on our strategic priorities across operations innovation and expanding portfolio and how these are translating into strong execution and sustained performance in 2025. First, in operations, our global high-quality manufacturing infrastructure remains a key competitive advantage, and we continue to be recognized for his quality track record and industry-leading reliability.
今天早上,我將就我們在營運、創新與擴充產品組合等策略優先事項提供最新進展,並說明這些如何在 2025 年轉化為強勁的執行力與持續的績效表現。首先在營運方面,我們全球高品質的製造基礎設施仍是關鍵競爭優勢,我們也持續因其品質紀錄與業界領先的可靠性而獲得肯定。
Each year, we make targeted investments in digitization and automation across our network to improve efficiency and scalability. We also stay focused on our cost structures through various operational excellence programs. These capabilities enable us to launch new complex products, help address work shortages and meet the needs of our customers and the patients we serve.
每一年,我們都在整個網路中進行有針對性的數位化與自動化投資,以提升效率與可擴展性。我們也透過各項營運卓越計畫,持續聚焦成本結構。這些能力使我們能推出新的複雜產品,協助因應人力短缺,並滿足我們客戶與所服務病患的需求。
Amneal has built one of the largest and most advanced US pharmaceutical manufacturing footprints anchored in New York, New Jersey with broad capabilities across urosolis, liquids, topicals, transdermals and complex formulations, making Made in America a core strategic advantage. In the second quarter, we announced our collaboration with EpiJet to start US injectable manufacturing, leveraging their blow-fill-seal technology capabilities.
Amneal 已建立美國規模最大且最先進的製藥製造版圖之一,以紐約與新澤西為核心,具備涵蓋 urosolis、液體、外用、經皮貼片與複雜配方等廣泛能力,使「美國製造」成為核心策略優勢。在第二季,我們宣布與 EpiJet 合作啟動美國注射劑製造,運用其吹灌封(blow-fill-seal)技術能力。
This partnership strengthens our ability to serve both commercial and government markets with large production capacity while supporting US emergency preparers and national health security. These expansion extends our leading US pharmaceutical manufacturing footprint and expands our domestic capabilities for future complex products in star dosage forms.
此合作夥伴關係強化我們以大規模產能服務商業與政府市場的能力,同時支援美國緊急備援與國家健康安全。這些擴張延伸我們在美國領先的製藥製造版圖,並擴大我們在未來複雜產品與無菌劑型方面的國內能力。
Turning to innovation. We are very pleased with the continued strong performance of CREXONT in the first year of launch. CREXONT is uniquely designed to deliver rapid onset and sustained efficacy giving Parkinson's patients more good on time with fewer daily doses. Our Phase 4 study remains on track, and we expect with real-world data to further reinforce CREXONT's clinical value and differentiation.
接著談創新。我們對 CREXONT 在上市第一年持續展現的強勁表現感到非常滿意。CREXONT 以獨特設計提供快速起效與持續療效,讓帕金森氏症患者以更少的每日服用次數,獲得更多「良好 on time」。我們的第 4 期研究仍按計畫推進,並預期透過真實世界數據進一步強化 CREXONT 的臨床價值與差異化。
Next, in our specialty business is Brekiya, the now approved DHE auto injector for migraine and cluster headache. This is the first and only auto-injector formulation of these well-established therapy. This paves the way for us to develop other drug device combination products that are clinically relevant for providers and can help patients in other branded therapeutic areas.
接下來,在我們的專科業務方面,Brekiya 是目前已獲核准、用於偏頭痛與叢集性頭痛的 DHE 自動注射器。這是此一成熟療法的首個且唯一的自動注射器劑型。這也為我們開啟道路,開發其他藥械組合產品,這些產品對醫療提供者具有臨床相關性,並可協助其他品牌治療領域的病患。
In GLP, once our strategic partnership with Metsera is advancing, we are building two state-of-the-art manufacturing facilities, one for high-value peptide drug substance production and the other for advanced sterile fill-finish capabilities. Metsera's lead programs are progressing well through development with impressive efficacy and strong product profile and time lines that are not too far out, positioning us to participate meaningfully in this high-growth market.
在 GLP 方面,隨著我們與 Metsera 的策略合作持續推進,我們正在建置兩座最先進的製造設施:一座用於高價值胜肽藥物原料(drug substance)生產,另一座用於先進的無菌充填與成品製程(fill-finish)能力。Metsera 的主要計畫在開發進程中表現良好,具備令人印象深刻的療效與強勁的產品特性,且時程不算遙遠,使我們得以在這個高成長市場中做出具實質意義的參與。
This collaboration draws on our core strength in complex pharmaceutical R&D and manufacturing through our differentiated integrated business model. We believe we can drive innovation at scale and deliver new impactful obesity therapies for patients. In our affordable medicines portfolio, we expect to launch 20 to 30 new products each year. We have launched 15 new products so far in 2025. In Q2, we were pleased to receive approval for our generic version of Pred Forte, a complex ophthalmic product.
此合作結合我們在複雜製藥研發與製造方面的核心優勢,並透過我們具差異化的整合式商業模式加以發揮。我們相信能以規模化方式推動創新,為病患帶來新的、具影響力的肥胖治療方案。在我們的平價藥品產品組合中,我們預期每年推出 20 到 30 項新產品。截至 2025 年目前為止,我們已推出 15 項新產品。在第二季,我們很高興獲得 Pred Forte 學名藥版本的核准,這是一項複雜的眼科產品。
Among upcoming key launches this year, there is Risperdal injection, (inaudible) a generic version of Restasis for dry eye and many more. Overall, our affordable medicine pipeline remains steep as robust, capable of producing new products for years.
今年即將到來的關鍵上市產品包括 Risperdal 注射劑、(聽不清)Restasis 乾眼症學名藥版本,以及更多產品。整體而言,我們的平價藥品研發管線仍然非常強勁且穩健,足以在未來多年持續產出新產品。
We are very pleased with our continued progress in developing complex products across key categories such as microspheres, liposomal and 552 injectables. We are also making strong, strong progress in inhalation, which will become a new vector of growth beginning next year with two commercial innovation product launches expected in 2026. As of Q2, there are 76 ANDAs pending approval out of which 67% are non-oral solids and 47 products in development, out of which 96% are non-oral solids.
我們對於在微球、脂質體以及 552 注射劑等關鍵類別的複雜產品開發持續取得進展感到非常滿意。我們在吸入劑型方面也取得非常、非常強勁的進展;自明年起,吸入產品將成為新的成長動能,預計於 2026 年推出兩項商業化創新產品。截至第二季,尚有 76 件 ANDA 待核准,其中 67% 為非口服固體;另有 47 項產品在開發中,其中 96% 為非口服固體。
We continue to prioritize our R&D portfolio and allocate investment towards higher-growth areas like specialty brands, injectables and biosimilars. In biosimilar we see an opportunely for Amneal to establish a leadership position in this space.
我們持續優先排序研發產品組合,並將投資配置至成長性更高的領域,例如專科品牌、注射劑與生物相似藥。在生物相似藥方面,我們看到 Amneal 有機會在此領域建立領導地位。
This year, we are filing five hours (inaudible) pipeline candidates with launches targeted for 2026 and 2027. The BLA filings for two (inaudible) biosimilars were submitted with goal dates in quarter four. Next, we look to submit the supplemental BLA for our back first in OBI and auto-injector in quarter four, formed by the BLA filing for biosimilar XOLAIR in quarter four.
今年,我們將提交五項(聽不清)管線候選產品,目標於 2026 年與 2027 年上市。兩項(聽不清)生物相似藥的 BLA 申請已提交,目標審查日期落在第四季。接著,我們預計在第四季提交我們 back first 的 OBI 與自動注射器的補充 BLA,並在第四季提交生物相似藥 XOLAIR 的 BLA 申請。
We are pleased that our (inaudible) OBI and auto-injector product as well as our biosimilar XOLAIR will be made in America, underscoring our commitment to high-quality US-based manufacturing and supply chain reliability. Recently, we shared positive Phase 3 data for biosimilar XOLAIR positioning us to be among the first entrants in the $3 billion market.
我們很高興我們的(聽不清)OBI 與自動注射器產品,以及我們的生物相似藥 XOLAIR 都將在美國製造,凸顯我們對高品質美國在地製造與供應鏈可靠性的承諾。近期我們分享了生物相似藥 XOLAIR 的正向第 3 期數據,使我們有望成為規模 30 億美元市場中最早進入者之一。
We are focused on advancing these programs and continuously adding new programs to expand our biosimilar portfolio. In summary, we have continued our strong operational momentum and execution in 2025. Our strategic focus on innovation, quality and manufacturing excellence sets our brand for sustainable growth and category leadership across our business over time.
我們專注推進這些計畫,並持續新增新專案以擴大我們的生物相似藥產品組合。總結而言,我們在 2025 年持續維持強勁的營運動能與執行力。我們在創新、品質與製造卓越方面的策略聚焦,將使我們的品牌隨時間推進實現可持續成長,並在各業務領域取得類別領導地位。
Thank you. And with that, I will hand it over to Tasos.
謝謝。接下來我把時間交給 Tasos。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Thank you, Chintu, and good morning, everyone. We're very pleased with our second quarter financial performance as the resiliency of our diversified business model, strong growth in our specialty business and focus on efficiency delivered revenue growth of 3%, adjusted EBITDA growth of 13% and adjusted EPS growth of 56%.
謝謝你,Chintu,各位早安。我們對第二季的財務表現感到非常滿意;多元化商業模式的韌性、專科業務的強勁成長以及對效率的聚焦,帶動營收成長 3%、調整後 EBITDA 成長 13%,以及調整後 EPS 成長 56%。
Furthermore, we reduced net leverage to 3.7 times versus 3.9 times adjusted EBITDA in December 2024 and fully refinanced our debt, which will reduce interest costs substantially and extend maturities to 2032. From the top line perspective, Q2 was another quarter of growth and total net revenues up 3%. Our affordable maintenance revenue of $433 million grew 1% on top of last year's exceptional growth of 14%.
此外,相較於 2024 年 12 月調整後 EBITDA 的 3.9 倍,我們將淨槓桿降至 3.7 倍,並完成債務的全面再融資,將大幅降低利息成本並把到期日延長至 2032 年。從營收端來看,第二季再度呈現成長,總淨營收增加 3%。我們的平價藥品營收為 4.33 億美元,在去年 14% 的卓越成長基礎上再成長 1%。
Our current quarter growth was driven by new products were 2024 and 2025 launches added $33 million. It is important to note that during the second quarter, our commercial teams built a strong foundation with our clients across another of new 505(b)(2) products, while our global supply teams completed a few production facilities upgrades.
我們本季的成長主要由新產品帶動,2024 年與 2025 年的上市產品合計貢獻了 3,300 萬美元。需要特別指出的是,在第二季,我們的商業團隊與客戶就另一項新的 505(b)(2) 產品建立了堅實基礎,同時我們的全球供應團隊也完成了數項生產設施升級。
The combination of multiple highly innovative products and enhanced manufacturing supply to meet market demand gives us confidence for even higher revenues in subsequent quarters. Q2 Specialty revenue was also very strong at $128 million as it grew 23% year over year. This growth was driven by our three main branded products with CREXONT adding 11 million; RYTARY, adding $9 million, up 19%; and UNITHROID adding $4 million, up 12%.
多項高度創新的產品與強化後、可滿足市場需求的製造供應相結合,使我們對後續季度實現更高營收充滿信心。第二季 Specialty(專科)營收同樣非常強勁,達 1.28 億美元,年增 23%。此成長主要由我們三項核心品牌產品帶動:CREXONT 增加 1,100 萬美元;RYTARY 增加 900 萬美元、年增 19%;UNITHROID 增加 400 萬美元、年增 12%。
We continue to be very pleased by the market acceptance of CREXONT and expect full year 2025 revenue in excess of our initial estimate of $15 million. In the second quarter, healthcare revenues of $163 million declined 4%, while gross margin increased by 540 basis points and operating income increased by 44%. As we discussed in the first quarter, we're very pleased by the financial performance of and the team's focus on higher profitability by maximizing the unique value we provide to the VA and DoD compared to the lower-margin distribution channel.
我們持續對 CREXONT 的市場接受度感到非常滿意,並預期 2025 全年營收將超過我們最初估計的 1,500 萬美元。第二季醫療保健(healthcare)營收為 1.63 億美元,下降 4%,但毛利率提升 540 個基點,營業利益增加 44%。如同我們在第一季所討論的,我們對財務表現以及團隊聚焦於提升獲利能力感到非常滿意;我們透過最大化相較於低毛利分銷通路、我們對 VA 與 DoD 所提供的獨特價值,來推動更高的獲利。
Let me now move down the P&L., where Q2 adjusted gross margins were very strong at 45.6%, up 470 basis points year over year. These gross margins were driven by favorable product mix in each of the three segments and ongoing operating efficiencies.
接著我來看損益表(P&L),第二季調整後毛利率非常強勁,為 45.6%,年增 470 個基點。這些毛利率主要受惠於三個事業部門各自的有利產品組合,以及持續的營運效率提升。
Notably, gross margins of affordable medicines grew 270 basis points to 44.3%. Our second quarter adjusted EBITDA of $184 million grew 13%, driven by top line growth, higher gross margins and higher investments in R&D and sales and marketing to ensure future growth.
值得注意的是,平價藥品(affordable medicines)的毛利率提升 270 個基點至 44.3%。我們第二季調整後 EBITDA 為 1.84 億美元,成長 13%,主要由營收成長、更高毛利率,以及為確保未來成長而增加對研發與銷售及行銷的投資所帶動。
Finally, we were extremely pleased by the 56% growth in adjusted earnings per share driven by the higher adjusted EBITDA, favorable foreign exchange and lower interest expense. Looking at our first half financial performance, our total company revenues grew 4%. Our adjusted EBITDA of $354 million grew 12%, and our adjusted EPS of $0.45 is up 50%.
最後,我們對調整後每股盈餘(EPS)成長 56% 感到非常滿意,主要由較高的調整後 EBITDA、有利的匯率變動以及較低的利息費用所驅動。從上半年財務表現來看,公司總營收成長 4%。調整後 EBITDA 為 3.54 億美元,成長 12%;調整後 EPS 為 0.45 美元,成長 50%。
We're also very pleased by the increased level of profitability as adjusted gross margin of 44.3% grew 290 basis points and adjusted EBITDA of 25% grew 180 basis points. Before I conclude with our updated 2025 financial guidance, I'll just start on four important topics.
我們也對獲利能力提升的幅度感到非常滿意:調整後毛利率 44.3% 提升 290 個基點,調整後 EBITDA 利潤率 25% 提升 180 個基點。在我以更新後的 2025 年財務指引作結之前,我先談四個重要主題。
First, we're excited about our multiple growth drivers, ensuring robust top line growth. This includes over 20 new product launches annually, strong uptake of CREXONT, the upcoming launch of Brekiya for migraine and cluster headaches, multiple new biosimilar launches next year and large new product opportunities available to the VA and DOD.
第一,我們對多項成長動能感到振奮,這將確保強勁的營收成長。其中包括每年超過 20 項新產品上市、CREXONT 的強勁導入、即將上市用於偏頭痛與叢集性頭痛的 Brekiya、明年多項新的生物相似藥上市,以及可提供給 VA 與 DoD 的大型新產品機會。
Second, from a tax perspective, and while we don't have full clarity, we have multiple levers to mitigate any potential negative impact. As we have discussed, we have one of the largest US manufacturing footprints in our industry. We have extensive experience with tech transfers. We have no meaningful exposure to Mexico, Canada, China or Europe and finally, no exposure to any most favorable nascent pricing action.
第二,就稅務角度而言,雖然我們尚未完全明朗,但我們有多項槓桿可用以緩解任何潛在的負面影響。如同我們先前所述,我們擁有本產業中規模最大的美國製造據點之一。我們在技術移轉方面具備豐富經驗。我們對墨西哥、加拿大、中國或歐洲沒有任何重大曝險;最後,我們也不受任何「最惠國」新興定價措施的影響。
Third, from a balancing perspective, we're extremely pleased by the full refinancing we opportunistically completed last week. In summary, we refinanced $2.7 billion of debt by issuing $2.1 billion in the new seven-year term loan B and a brand-new $600 million, seven-year senior secured note.
第三,就資產負債表(balancing)角度而言,我們對上週把握時機完成的全面再融資感到非常滿意。總結來說,我們透過發行 21 億美元新的七年期 B 類定期貸款(term loan B),以及全新的 6 億美元七年期優先擔保票據,為 27 億美元債務完成再融資。
The refinancing was extremely well received and oversubscribed many times over and achieved long-term interest cost reduction of more than $33 million annually and extended maturity to 2032 versus 2028. Fourth point worth mentioning is that because of the new federal tax legislation, we expect about $46 million in cost tax savings, most of which will occur in 2026, improving our customer.
此次再融資反應極佳、超額認購數倍,並使長期利息成本每年降低超過 3,300 萬美元,同時將到期日由 2028 年延長至 2032 年。第四點值得一提的是,由於新的聯邦稅法,我們預期可節省約 4,600 萬美元的稅務成本,其中大部分將發生在 2026 年,進而改善我們的客戶。
This benefit is primarily driven by the immediate expensing of R&D and upfront depreciation of assets. The strength of our first half performance in the multiple levers of growth drivers and solid execution, we're pleased to update our 2025 financial guidance. For revenues, we continue to expect $3 billion to $3.1 billion for increasing adjusted EBITDA by about $15 million in the range of $665 million and $685 million.
此項效益主要來自研發費用可立即費用化,以及資產的前期加速折舊。基於我們上半年表現強勁、具備多項成長動能槓桿且執行穩健,我們很高興更新 2025 年財務指引。在營收方面,我們仍預期為 30 億至 31 億美元;調整後 EBITDA 預計增加約 1,500 萬美元,落在 6.65 億至 6.85 億美元區間。
For increasing our adjusted EPS by about $0.05 between $0.70 and $0.75. And we're also raising our operating cash flow guidance excluding discrete items by about $20 million in the range of $300 million and $330 million.
調整後 EPS 預計提高約 0.05 美元,介於 0.70 至 0.75 美元之間。此外,我們也將排除一次性項目(discrete items)後的營運現金流指引上調約 2,000 萬美元,至 3.00 億至 3.30 億美元區間。
With that, I'll turn the call back to Chirag.
接下來,我把電話交回給 Chirag。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Tasos. Q2 results and increased 2025 guidance reflects the continued strength of our diverse business. We are confident in our ability to continue advancing in this new chapter of growth towards our goal of being America's number one affordable medicines company.
謝謝你,Tasos。第二季成果以及上調的 2025 年指引,反映出我們多元化業務的持續強勁。我們有信心在這個新的成長篇章中持續推進,朝著成為「美國第一的平價藥品公司」這一目標邁進。
Let's now open the call for question and answers.
現在我們開放提問與回答。
Operator
Operator
(Operator Instructions) David Amsellem, Piper Sandler.
(接線員指示)David Amsellem,Piper Sandler。
David Amsellem - Senior Research Analyst
David Amsellem - Senior Research Analyst
Just a couple from me. First on CREXONT and RYTARY in the overall Parkinson's franchise. As we move through '25 and into '26, with the LOE of RYTARY, how should we think about when the Parkinson's franchise reaches a trough?
我這邊只有兩個問題。第一個是關於整體帕金森氏症產品線中的 CREXONT 與 RYTARY。當我們走過 2025 年並進入 2026 年,隨著 RYTARY 的 LOE(專利到期/獨占期到期),我們應該如何看待帕金森氏症產品線何時觸底?
And when you think you'll be in a position to return that business to growth once you've absorbed the full impact of the LOE? Just help us understand that particularly as we move into next year? That's number one.
以及在你們吸收 LOE 的全部影響之後,預計何時能讓該業務恢復成長?特別是當我們進入明年時,請協助我們理解這一點。這是第一個。
And then number two, on Metsera collaboration. I noticed you talked about commercial manufacturing for -- at cost plus a margin. Just wondering how profitable that is going to be and the extent to which that those economics ultimately will expand your overall profitability?
第二個是關於與 Metsera 的合作。我注意到你提到商業化製造是以「成本加成(cost plus a margin)」的方式進行。想請問這會有多高的獲利性,以及這些經濟條件在多大程度上最終會提升你們整體獲利能力?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
This is Tasos. So let me take the first one. So with -- just to directly answer your question in terms of the growth of the business, just from a context perspective, So last year, RYTARY did about $210 million worth of revenue. And obviously, we had no CREXONT. My gut feel this year, as you know, even though the LOE of RYTARY was on July 31, there has been no approval for a generic RYTARY.
我是 Tasos。我先回答第一個。就直接回答你關於業務成長的問題,先提供一些背景:去年 RYTARY 的營收約 2.10 億美元。而且顯然當時還沒有 CREXONT。依我直覺,今年如你所知,即使 RYTARY 的 LOE 是在 7 月 31 日,但目前尚未有學名藥 RYTARY 獲得核准。
So that's in helping us this year. And it also, I think, is going to help us in the short term next year, whenever generics become available. Our gut feel is this year with probably CREXONT doing, let's say, $55 million or so, maybe RYTARY does about $150 million.
因此這在今年對我們有所幫助。而且我認為,短期內在明年也會對我們有所幫助,直到學名藥開始上市為止。我們的直覺是,今年 CREXONT 可能做到例如約 5,500 萬美元,而 RYTARY 可能約 1.50 億美元。
So essentially, the combined portfolio is essentially flat to last year from a revenue perspective. EBITDA is a bit of a drag this year, which we're obviously able to overcome because of the growth of the rest of the business and just reflects the investments we need to make to grow CREXONT.
因此,從營收角度來看,合併後的產品組合基本上與去年持平。今年 EBITDA 稍微有些拖累,但我們顯然能夠克服,因為其他業務的成長足以支撐;這也反映了我們為了推動 CREXONT 成長所必須進行的投資。
The trough, we believe, comes next year, right, from a revenue perspective. Because next year, RYTARY probably will have, obviously, more of a generic competition than this year. But at the same time, CREXONT is growing very, very rapidly.
我們認為,從營收角度來看,低谷會出現在明年,對吧?因為明年 RYTARY 很可能會面臨比今年更激烈的學名藥競爭。但同時,CREXONT 正在非常、非常快速地成長。
So I think the trough comes next year from a revenue perspective, okay? But I believe from an EBITDA perspective, trough is probably -- I don't expect much of dilution than this year from an EBITDA perspective.
所以我認為,從營收角度來看,低谷會在明年,好嗎?但我相信從 EBITDA 的角度來看,低谷大概——我不預期 EBITDA 方面會比今年有更大的稀釋。
Because this year, we already observed a substantial headwind to EBITDA because of the investments of CREXONT. But nevertheless, even if there is a bit of a headwind next year from an EBITDA perspective as well, we feel confident we will be able to overcome this as the rest of the business will more than offset that.
因為今年我們已經觀察到,由於對 CREXONT 的投資,EBITDA 受到相當大的逆風影響。不過,即便明年在 EBITDA 角度也會有一些逆風,我們仍有信心能夠克服,因為其他業務的表現將足以、甚至超過地抵消這些影響。
So at the end of the day, trough comes next year, highly confident we will be overcoming because we're trying to drive the total business to continue to grow top line and bottom line. So hopefully, that works for you. Let me turn it to Chirag on Metsera.
所以歸根結底,低谷會在明年;我們非常有信心能夠度過,因為我們正努力推動整體業務在營收端與獲利端持續成長。希望這樣能回答你的問題。我把時間交給 Chirag 談 Metsera。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yes. So David, Metsera collaborations moving forward very awesome. (inaudible) so any signed this engineers that had worked, my brother, everybody's and we work with Clive and with team over there. Great progress, and we could not be more happy than this about partnership. It is very properly structured as we have taken a lot of risk upfront building the sites.
是的。所以 David,Metsera 的合作往前推進得非常棒。(聽不清)所以任何已簽署的這些工程師都已經投入運作,我的兄弟、大家都在,我們也與 Clive 以及那邊的團隊合作。進展非常好,我們對這個合作夥伴關係的滿意程度再高也不為過。它的架構設計得非常妥當,因為我們在前期承擔了很大的風險來建置這些場址。
So we would expect more margins than typical CMO or CDMO because we have taken upfront risk. So those -- we are not sizing of the margins at this point, but they are higher than, obviously, the generics margins much higher --
因此,我們預期毛利率會高於典型的 CMO 或 CDMO,因為我們承擔了前期風險。所以——我們目前不便量化毛利率,但它們會高於、顯然也遠高於學名藥的毛利率——
And second point is international markets, which we control the marketing. We do not know yet exactly what price it would be sold at, but give you the reference we launched Manzaro in India at $160 a month. So of course, there will be some Ozempic generic competition, and we hear that it would be launching at $60, $80 a month for a monthly treatment.
第二點是我們掌控行銷的國際市場。我們目前還不確定最終售價會是多少,但給你一個參考:我們在印度推出 Manzaro 的價格是每月 160 美元。當然,之後會有一些 Ozempic 的學名藥競爭,我們聽說其月療程價格會在 60 到 80 美元推出。
So you can see it's a substantial opportunity for us, and we have 20 rights to 20 countries. And India will be setting the prices for most of the countries. And I don't think it will be lower than India's prices in any of those countries. And a significant number of patients that could be on this therapy.
所以你可以看到,這對我們而言是相當可觀的機會,而且我們擁有 20 個國家的權利。印度將會為多數國家定錨價格。我不認為在任何一個國家,價格會低於印度的價格。而且可能會有相當大量的病患使用這項療法。
The India number at this price somewhere between $60 to $160. I was there, the product is in shortage already is some 50 million patient. So these are large numbers of patients, volume will drive margins and higher penetration we could do would be having significant revenue.
以印度來看,在這個價格帶大約介於 60 到 160 美元之間。我人在那邊時,產品已經出現短缺,病患數大約有 5,000 萬。所以這是非常龐大的病患基數;量能會帶動毛利,而我們若能提高滲透率,就會帶來可觀的營收。
When we'll be sizing all these starting from beginning of 2026. I would say these are very significant opportunities for us for supplying Metsera as well as for our all international marketing. So that's for Metsera.
我們會從 2026 年初開始逐步量化這些機會。我會說,無論是供應 Metsera,或是我們所有的國際行銷,這些對我們而言都是非常重大的機會。以上是關於 Metsera。
Operator
Operator
Leszek Sulewski, Truist Securities.
Leszek Sulewski,Truist Securities。
Leszek Sulewski - Analyst
Leszek Sulewski - Analyst
First on the Parkinson's franchise, maybe just provide a latest status of the RYTARY generic launches. And also, can you maybe provide some additional commentary on where you stand with the reimbursement?
首先關於帕金森氏症產品線,能否提供一下 RYTARY 學名藥上市的最新狀況?另外,能否再補充一些你們在給付/報銷方面的進展?
And separately, what's the update on the regulatory approval process across some of the other partners internationally that you've disclosed before? And maybe provide any additional time lines that you'd expect on your international -- or your launch in India on the product, maybe how do you think about the size of that opportunity?
另外,你們先前披露過的一些其他海外合作夥伴,在各國的法規核准流程目前進展如何?也請提供你們對國際市場——或在印度推出該產品——可能的時間表更新,以及你們如何看待那個機會的規模?
And then separately, maybe just a longer view, as you're capturing some of the uptake from these partnerships, including Metsera and others and lean more into innovative products. How are you thinking about the overall gross margin profile for the enterprise moving into '27 and beyond?
再另外,從更長期的角度來看,隨著你們透過包括 Metsera 在內的合作夥伴關係帶動採用、並更偏向創新產品,對於公司整體在 2027 年及之後的毛利率輪廓,你們是如何思考的?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Yes. So let me take -- I'll take the RYTARY generic question, then I'll pass it over to Joe, who heads up commercial operations, commercial business or specialty then I'll turn it over to Chirag and Chintu for some of the partnerships and I'll tackle the margin profile.
是的。我先回答 RYTARY 學名藥的問題,接著把問題交給負責商業營運/商業業務或專科領域的 Joe,然後再交給 Chirag 和 Chintu 談一些合作夥伴相關事項,最後我會回到毛利率輪廓。
So in terms of generic, so, so far, so Teva has 180 days exclusivity on the generic RYTARY. They currently have not been approved. And frankly, I know as much as you do on when that may happen, right? So that's as much as I can tell you, and so forth.
就學名藥而言,到目前為止,Teva 對 RYTARY 學名藥擁有 180 天的獨家期。他們目前尚未獲得核准。坦白說,何時可能發生,我知道的跟你一樣多,對吧?所以我能告訴你的就這些,等等。
Our view is it's a sizable opportunity. We expected in our planning that generics were going to become available August 1. Obviously, this what I will call short-term delay helps us from a financial perspective. It allows us to reinvest in the business.
我們的看法是,這是一個相當大的機會。在我們的規劃中,原本預期學名藥會在 8 月 1 日上市。顯然,這個我稱之為短期的延遲,從財務角度對我們是有利的。它讓我們能夠把資金再投入到業務中。
It allows us to increase our guidance. But at some point in time, there will be generics maybe little later on this year, sometime next year, and we'll be in a great position to overcome any headwind that may come out of that. So I think that's the answer to your first question. Let me turn it over to Joe to give you an update on the reimbursement on CREXONT.
它也讓我們能夠上調財測指引。但在某個時間點,學名藥終究會出現,可能是今年稍晚、也可能是明年某個時候;而我們將處於很好的位置,去克服由此帶來的任何逆風。所以我想這就是你第一個問題的答案。我把時間交給 Joe,請他更新 CREXONT 的給付/報銷進展。
Joe Renda - Senior Vice President, Chief Commercial Officer - Specialty
Joe Renda - Senior Vice President, Chief Commercial Officer - Specialty
Yes. Les, thanks for the question. We've been really pleased with coverage so far with CREXONT in the market. Actually, it's above our expectations. We are anticipating around 50% coverage so far this year.
好的。Les,謝謝你的問題。到目前為止,CREXONT 在市場上的保險覆蓋情況讓我們非常滿意。事實上,這高於我們的預期。我們預期今年迄今的覆蓋率大約在 50% 左右。
We've garnered now over 60% commercial coverage, which includes some of the biggest payers in the market, United, CVS, VA, DOD. So really pleased with coverage, and we anticipate that to continue because we're in a good dialogue with the payers related to some of the Part D plans. So we're looking to land those. So our goal was always around 70% coverage. We're well on our way there.
我們目前已取得超過 60% 的商業保險覆蓋,其中包括市場上一些最大的支付方:United、CVS、VA、DOD。所以我們對覆蓋進展非常滿意,也預期會持續改善,因為我們正就一些 Part D 計畫與支付方保持良好對話。因此我們希望把那些也拿下來。我們的目標一直是約 70% 的覆蓋率。我們正朝這個方向穩步前進。
And the feedback for the market continues to be really strong from our key prescribers. So we're anticipating that the growth we're seeing is going to continue, and it's partly because of that great access that we've created so far.
此外,市場端來自我們關鍵處方醫師的回饋仍然非常強勁。因此我們預期目前看到的成長將會延續,而其中一部分原因正是我們迄今所建立的良好可近性(access)。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Let me take a crack also at some of the questions more about regulatory progress on some of the ex US business or the margin profile with those partnerships. So what we have said, right, is that in -- over the course of time, 99.9% of our revenue is US-based, right? So that leaves a lot of wide space, call it, ex US.
我也來嘗試回答一些問題,主要是關於美國以外業務在監管進展方面的情況,或是與那些合作夥伴相關的利潤率結構。所以我們一直說,對吧,隨著時間推進,我們99.9%的營收都來自美國,對吧?因此,這就留下了很大的空間,也就是所謂的美國以外市場。
So we have made the strategic choice that the best way for us from a capital allocation perspective is instead of trying to build the infrastructures in those markets, right, which is -- has a very long-term payback period to develop the partnership model for all markets, except India.
因此,我們在策略上做出選擇:從資本配置的角度來看,對我們而言最好的方式是——與其嘗試在那些市場建立基礎設施(對吧),那樣的投資回收期非常長——不如在除印度以外的所有市場採用合作夥伴模式。
And obviously, there is a lot of our own heritage in India. We have 6,000 employees already over there. And more importantly, if you think about India, the standard of living is growing substantially. The size of the pharmaceutical market there is supposed to grow -- is expected to grow dramatically.
而且很明顯,我們在印度有很深的自身傳承。我們在那裡已經有6,000名員工。更重要的是,如果你看印度,生活水準正在大幅提升。當地的製藥市場規模據說將會成長——預期會大幅成長。
So combination of our heritage, combination of our existing infrastructure in India, a relevant product portfolio and a very large market, it's only made sense to extend to for us to launch our own Amneal brand in those -- in that market.
因此,結合我們的傳承、我們在印度既有的基礎設施、具相關性的產品組合以及非常龐大的市場規模,我們在那個市場推出自有的 Amneal 品牌,對我們而言是最合理的。
And the uptake is growing very nicely. We have a few hundred people. We do -- we've established a commercial based in Mumbai, a few hundred commercial payments we're building it out. Early days of the product portfolio launching there, and that's going to build over the course of time. You shouldn't expect anything drastic over the next couple of years, but that's going to build over the course of time.
而且市場接受度成長得非常不錯。我們有幾百人。我們——已在孟買建立商業據點,有幾百名商業人員,我們正在擴建。目前仍是產品組合在當地上市的早期階段,這會隨著時間逐步擴大。未來幾年你不應期待有任何劇烈變化,但它會隨時間逐步累積。
In the rest of the markets, we out-licensed CREXONT in Europe. So that regulatory process is where it's in process. So that's going to come over the next couple of years of product approval and slowly building that revenue portfolio.
在其他市場方面,我們已將 CREXONT 在歐洲進行對外授權。因此,監管流程正在進行中。所以在未來幾年,將會陸續完成產品核准,並逐步建立那部分的營收組合。
So that's a little bit -- I think those are the two main kind of, what I will call, drivers of growth of our international business over the next few years. From a margin perspective, listen, we are not in the business of diluting margin.
所以這大概就是——我認為,這是未來幾年我們國際業務成長的兩個主要驅動因素。從利潤率角度來看,聽著,我們不做稀釋利潤率的事。
So what you should expect from us is continue to drive gross margin increases steadily over the course of time. Our adjusted EBITDA to revenue, it's been hovering at about 22.5%. You should expect this over the course of time to increase.
因此,你應該期待我們持續、穩健地推動毛利率隨時間提升。我們的調整後 EBITDA 對營收比率一直徘徊在約22.5%。你應該期待這個比率會隨時間提高。
And we're not doing anything to do anything dramatic because we want to continue to invest in the business because we see a tremendous amount of growth, whether or not it's in the injectables, biosimilars, international, I just mentioned it. But we're not in the business of diluting margins or diluting our cash flow.
而且我們不會做任何戲劇性的事情,因為我們希望持續投資於業務,因為我們看到非常可觀的成長,不論是在注射劑、生物相似藥、國際市場——我剛剛提到的。但我們不做稀釋利潤率或稀釋現金流的事。
So with that, let me turn it over to Chintu-ji or Chirag to see if they have anything else to add?
那麼,接下來我把時間交給 Chintu-ji 或 Chirag,看看他們是否還有其他補充?
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Thank you, Tasos. I just wanted to add on international partnership. First of all, we are very happy and pleased with CREXONT and how all the testimony for patients and our partners in Europe and LatAm are very pleased, and we are very excited. And we hope to launched these products in Europe by late 2026 and in India late '26 to early '27.
謝謝你,Tasos。我只是想補充一下國際合作夥伴的部分。首先,我們對 CREXONT 非常滿意也很高興;無論是對病患的效益,或是我們在歐洲與拉丁美洲的合作夥伴都非常滿意,我們也非常振奮。我們希望在2026年末於歐洲推出這些產品,並在印度於2026年末到2027年初推出。
So our regulatory applications are moving well. And we're excited plus we have a diversified manufacturing footprint and a cost advantage, we are also qualifying our India site for CREXONT to improve margins. Just wanted to add that.
因此,我們的監管申請進展順利。而且我們很振奮;再加上我們擁有多元化的製造佈局與成本優勢,我們也正在讓印度廠區通過 CREXONT 的資格認證,以提升利潤率。只是想補充這一點。
Operator
Operator
Chris Schott, JPMorgan.
JPMorgan 的 Chris Schott。
Unidentified Participant
Unidentified Participant
This is Ekaterina on for Chris. So my question just around guidance. I think the revenue range does imply a bit of a step-up as we think about revenues and the second half versus the first half of the year. Can you maybe elaborate what are the main drivers of this? I'm assuming some of this is the timing of new launches and perhaps the (inaudible) RYTARY, but just anything else to keep in mind.
我是代替 Chris 的 Ekaterina。所以我的問題是關於財測指引。我認為營收區間確實暗示,若比較下半年與上半年,下半年營收會有一定幅度的提升。你能否說明一下主要驅動因素是什麼?我猜其中一部分是新產品上市時點,或許也包括(聽不清)RYTARY,但還有沒有其他需要留意的?
And second question just around tariffs. Just latest thoughts on what these could be for the industry and Amneal. And I think specifically, what are you hearing out of Washington on how generic products and API could be treated as we think about the 150% or 250% tariffs that are being thrown around?
第二個問題是關於關稅。想請教你們對這些關稅對產業以及 Amneal 可能造成影響的最新看法。特別是,關於外界提到的150%或250%關稅,你們從華盛頓那邊聽到的消息是:學名藥產品與 API 可能會如何被對待?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Ekaterina, I can take the first one. We expect the stronger second half from a revenue perspective than the first half. And as you said, there is nothing fundamentally different other than the typical, what I would call, cables of new product introductions. So products that we launched late in 2024, early 2025, they keep building momentum over the course of time. That's number one.
Ekaterina,第一個我可以回答。我們預期從營收角度來看,下半年會比上半年更強。如你所說,並沒有任何根本性的不同,主要只是典型的——我會稱之為——新產品導入的節奏。也就是我們在2024年末、2025年初推出的產品,會隨時間持續累積動能。這是第一點。
Number two is on vast majority of the products we were expecting to launch in 2025, you have already launched, but there were just a few more that are supposed to be coming in Q3 and Q4. So those will add to the revenue growth. And the third point is really we're looking at, as I mentioned in my script, in Q1 and Q2, we completed a number of facility upgrades that prevented us from meeting market demand, primarily on our injectable portfolio.
第二點是,我們原本預期在2025年推出的產品中,絕大多數你們已經看到我們推出了,但還有少數幾個預計會在第三季與第四季推出。因此,這些會帶動營收成長。第三點是,正如我在講稿中提到的,在第一季與第二季,我們完成了多項廠房升級,這使我們無法滿足市場需求,主要是在我們的注射劑產品組合上。
Now though is essentially behind us in just freeze up capacity and just improves our global supply ability to meet market demand. So all of those things will play in the second half of the year to have stronger revenue performance than the first half.
不過現在基本上已經告一段落,等於釋放了產能,並提升我們在全球供應端滿足市場需求的能力。因此,這些因素都會在下半年發揮作用,使下半年營收表現強於上半年。
And then obviously, we're looking for growth from a top line perspective, going into 2026 and 2027 with a strong tailwind behind us. I'll turn it over to Chirag and to maybe tell us a little bit about all their adventures coming out of Washington, D.C.
然後很明顯地,從營收(top line)的角度來看,我們也在展望2026與2027年的成長,背後有強勁的順風支撐。我把時間交給 Chirag,請他談談他們在華盛頓特區那邊的各種「冒險」最新進展。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Okay. That's the hardest job to do. So we've been meeting and giving our perspective to the administration, which is rightfully focused on two things, what is driving these pharma investigation. The one is national security. So heavily overreliance and antibiotics will be like 95% of key starting material coming from China.
好的。那是最難做的工作。所以我們一直在與政府會面並提供我們的觀點;政府理所當然地聚焦在兩件事上,也就是是什麼在推動這些藥品調查。第一是國家安全。例如在抗生素方面,對中國的高度依賴——關鍵起始物料可能有95%來自中國。
And many -- we hardly make anything in the United States, even finished goods, it's less than 2%. So take each of these critical categories, we have virtually no manufacturing in the United States. Second thing is socioeconomics, obviously, that it creates American jobs and more factories, more plants in the United States.
而且很多——我們在美國幾乎不生產任何東西,即使是成品,比例也不到2%。所以你看每一個這些關鍵類別,我們在美國幾乎沒有製造能力。第二件事是社會經濟面,顯然是要創造美國就業機會,並在美國建立更多工廠、更多生產基地。
So with that, we are not negotiating, but we've been putting new solutions because if you put a 150%, as you said, or 200% tariff is going to be chaotic because Nobody knows how long the tariffs would stay. So if there are such a large tariffs, obviously, the pricing would have to go up to our customers because we have to keep supplying the products and we are keep making money, and this is not a salon.
因此,基於這點,我們不是在談判,而是一直在提出新的解決方案,因為如果如你所說加徵150%或200%的關稅,將會造成混亂,因為沒有人知道關稅會維持多久。所以如果關稅如此之高,顯然我們必須把價格上調轉嫁給客戶,因為我們必須持續供應產品,而且我們也要持續獲利,這不是沙龍。
It's all the companies. We are least impacted because they're almost two-thirds of manufacturing values in the United States. But they could create shortages as well.
這是所有公司都一樣。我們受到的影響最小,因為美國境內的製造價值幾乎有三分之二在那裡。但它們也可能造成短缺。
I may not be the solution where administration is trying to do and which we fully support is for the national security in the production of critical products in the United States from the key starting material API to finished goods by creating a demand for American made products because it will be obviously expensive products to make in America compared to coming out of China or in China and India.
我可能不是解方;政府正在嘗試做、而我們也全力支持的是:為了國家安全,在美國境內生產關鍵產品,從關鍵起始原料API到成品,透過創造對美國製造產品的需求來達成,因為相較於從中國出來,或在中國與印度製造,在美國生產顯然會更昂貴。
So with all that, it's still unknown. We'll see what happens. It's still under investigation. As of now, pharma is exempted from all tariffs, we'll stay tuned.
所以在這一切之下,仍然是未知數。我們會看看會發生什麼事。目前仍在調查中。截至目前,製藥業仍豁免於所有關稅,我們會持續關注。
Operator
Operator
Matt Dellatorre, Goldman Sachs.
高盛的Matt Dellatorre。
Matthew Dellatorre - Analyst
Matthew Dellatorre - Analyst
And congrats on the continued progress. Maybe first, just a follow-up on the prior question on the revenue guide. Should we expect the generics and distribution segments to inflect or catch up in second half? And then second question, post the recent debt refinancing.
也恭喜你們持續取得進展。也許先就先前關於營收指引的問題追問一下。我們是否應預期學名藥與配銷事業在下半年出現拐點或追上進度?第二個問題是,在近期債務再融資之後。
What are your latest thoughts on the potential vertical integration of your biosimilars business in terms of timing or likelihood? And then maybe more broadly, how does this increased flexibility that you now have impact your broader capital allocation strategy?
你們對於生物相似藥業務可能進行垂直整合的最新看法是什麼,就時程或可能性而言?更廣泛地說,現在你們擁有的更高彈性,如何影響你們更整體的資本配置策略?
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Matt, this is Tasos. First on healthcare, we expect growth in the second half, substantially more growth in the second half. There is -- and that's really driven by what I call stability on the distribution channel. So at this point in time, point number one. And number two is we expect our government business to accelerate the growth that we have already seen this year because there is a number of large product plans.
Matt,我是Tasos。先談醫療保健,我們預期下半年會成長,而且下半年的成長會顯著更高。這主要是由我所稱的配銷通路穩定性所驅動。所以就目前而言,這是第一點。第二點是,我們預期政府業務將加速今年迄今已看到的成長,因為有若干大型產品計畫。
I don't want to talk specifics. There is at least one or two large product opportunities that will become available in Q3 and (inaudible) will be in a position to capitalize on that opportunity. That's number one. From a refinancing perspective, before I turn it over to Chirag to talk about.
我不想談具體細節。至少有一到兩個大型產品機會會在第三季釋出,而(聽不清)將能夠把握這個機會。這是第一點。就再融資而言,在我把話交給Chirag說明之前。
So from a refinancing perspective, as I mentioned before, that was just incredibly successful, substantially reduces our interest expense, depending what multiuse it decreases our interest expense between 16% and 20% per year.
所以就再融資而言,如我先前提到的,那次操作非常成功,顯著降低了我們的利息費用,視(聽不清)而定,每年可使我們的利息費用下降16%到20%。
So that's a dramatic improvement. Number one, extends maturities by four years to 2032, and we don't expect this to change our capital allocation policy. So over the course of time, what we have said is we want to make sure that we fund our business appropriately and capitalize on the opportunities that we have, number one, and also deleveraging over the course of time is really important to us and that doesn't need to be linear, right, every single quarter, every single year.
這是非常顯著的改善。第一,將到期日延長四年至2032年,我們不預期這會改變我們的資本配置政策。因此,隨著時間推進,我們所說的是:第一,我們要確保適當為業務提供資金並把握我們擁有的機會;同時,隨時間推進去槓桿對我們也非常重要,而且不需要是線性的,對吧,不是每一季、每一年都要線性下降。
But over the course of time, I think we've done a really good job essentially cutting leverage by half in the last four or five years. So that's our area of focus. Chirag, anything else?
但隨著時間推進,我認為我們在過去四、五年基本上把槓桿水準砍半,做得非常好。所以這是我們的重點領域。Chirag,還有要補充的嗎?
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yes, I think you and your second question, Matt on how -- when do we look to integrate? So first of all, biosimilars the entire market, it's a race strength now. We have fast we can execute FDA has been very cooperative along with MHRA, EMA, entire world, obviously, for obvious reasons, tremendous cost savings, but most importantly, it creates more access, more patients.
是的,我想你第二個問題,Matt,關於我們何時會考慮整合。首先,生物相似藥整個市場現在是一場競賽。我們執行得越快越好;FDA一直非常配合,MHRA、EMA以及全球各地也都很配合,顯然是出於明確原因:巨大的成本節省,但更重要的是,它帶來更多可近性、更多病患。
We have seen 2.5 times more volume because of more excess because of lower prices. So how many new patients are getting this product. So total support from all of the regulatory agency government agencies.
我們看到因為更高的可近性、因為更低的價格,量增加了2.5倍。也就是有多少新病患正在使用這個產品。因此,所有監管機構與政府機關都全力支持。
I know we had a bad start with Humira as a market, but it now -- there are 100 biologics, only 20 are being worked on, 80 are not being worked on. So our goal is we have done this so well with complex generics products, and we have invested so much in this. We could do this. We could have a pipeline of 30 products, 35.
我知道Humira作為一個市場一開始表現不佳,但現在——有100個生物製劑,只有20個正在開發,另外80個沒有在開發。所以我們的目標是:我們在複雜學名藥產品上做得非常好,也在這方面投入了很多。我們可以做到。我們可以有30個、35個產品的產品線。
We can keep going and make a lot of products in the United States and India and have this combination, which allows us a global supply and global cost position and much faster execution on a number of products. So we look to -- since it's a rance, we look to do it as soon as possible.
我們可以持續推進,並在美國與印度生產大量產品,形成這樣的組合,使我們具備全球供應與全球成本優勢,並能在多個產品上更快執行。所以我們希望——既然這是一場競賽,我們希望盡快完成。
But we'll be very disciplined and obviously do the deal, which doesn't blow any of the -- we have worked hard to get our debt-to-EBITDA ratio down. So we would like to maintain or have some flexibility there and then set up a deal which we can afford and provides tremendous growth to Amneal going forward. We see this as a great business for next 10 years.
但我們會非常自律,並且顯然會做一筆不會破壞任何——我們一直努力把淨負債對EBITDA比率降下來。所以我們希望維持或保有一些彈性,然後設計一筆我們負擔得起、並能為Amneal未來帶來巨大成長的交易。我們認為這將是未來10年的一門很棒的業務。
Operator
Operator
Thank you. This concludes our Q&A session. I'll hand back to Chirag for closing remarks.
謝謝。以上結束我們的問答環節。我把時間交回給Chirag做結語。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you very much, everybody. Have a great day today.
非常感謝各位。祝大家今天愉快。
Operator
Operator
Thank you. This concludes today's call. Thank you for joining. You may now disconnect your lines.
謝謝。以上結束今天的電話會議。感謝各位參與。各位現在可以掛線。